Trial Profile
A phase II study of atezolizumab with rituximab, gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large b-cell lymphoma who are not candidates for high-dose therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Gemcitabine; Oxaliplatin; Rituximab; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms ARGO
- 19 Aug 2022 Status changed from active, no longer recruiting to discontinued.
- 26 Jul 2021 Planned End Date changed from 1 Jun 2023 to 1 Sep 2021.
- 26 Jul 2021 Status changed from completed to active, no longer recruiting.